Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZH2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,664
Award facts
- Contract value 100% obligated
- $38,664.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,664.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, awarded on January 23, 2026, with an ultimate completion date of January 26, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy that authorizes the issuance of delivery orders for pharmaceutical products to support Department of Defense healthcare operations globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with documented performance across numerous delivery orders issued by the DLA's Medical Supply Chain division. The company's portfolio encompasses an extensive range of pharmaceuticals including branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V contract, which positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors, features a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods, enabling the company to serve as a sustained source for the diverse pharmaceutical requirements of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FCZH2?
SPE2DR26FCZH2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FCZH2 worth?
The government has obligated $38,664 on SPE2DR26FCZH2.
Is contract SPE2DR26FCZH2 an order under another contract?
Yes. SPE2DR26FCZH2 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZH2 competed?
The extent of competition for SPE2DR26FCZH2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award